Michael Silverberg to Treatment Outcome
This is a "connection" page, showing publications Michael Silverberg has written about Treatment Outcome.
Connection Strength
0.678
-
The HIV Care Cascade Measured Over Time and by Age, Sex, and Race in a Large National Integrated Care System. AIDS Patient Care STDS. 2015 Nov; 29(11):582-90.
Score: 0.102
-
Differences in Response to Antiretroviral Therapy by Sex and Hepatitis C Infection Status. AIDS Patient Care STDS. 2015 Jul; 29(7):370-8.
Score: 0.099
-
Race/ethnicity and risk of AIDS and death among HIV-infected patients with access to care. J Gen Intern Med. 2009 Sep; 24(9):1065-72.
Score: 0.066
-
Effectiveness of highly-active antiretroviral therapy by race/ethnicity. AIDS. 2006 Jul 13; 20(11):1531-8.
Score: 0.054
-
Nonsurgical management of binocular diplopia induced by macular pathology. Arch Ophthalmol. 1999 Jul; 117(7):900-3.
Score: 0.033
-
Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C. JAMA Netw Open. 2019 06 05; 2(6):e194765.
Score: 0.033
-
Hepatitis C treatment uptake and response among human immunodeficiency virus/hepatitis C virus-coinfected patients in a large integrated healthcare system. Int J STD AIDS. 2019 06; 30(7):689-695.
Score: 0.032
-
Association of raltegravir use with long-term health outcomes in HIV-infected patients: an observational post-licensure safety study in a large integrated healthcare system. HIV Clin Trials. 2018 10; 19(5):177-187.
Score: 0.031
-
A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease. Eur Urol. 2018 01; 73(1):129-138.
Score: 0.029
-
Preexposure Prophylaxis for HIV Prevention in a Large Integrated Health Care System: Adherence, Renal Safety, and Discontinuation. J Acquir Immune Defic Syndr. 2016 Dec 15; 73(5):540-546.
Score: 0.028
-
Response to Therapy in Antiretroviral Therapy-Naive Patients With Isolated Nonnucleoside Reverse Transcriptase Inhibitor-Associated Transmitted Drug Resistance. J Acquir Immune Defic Syndr. 2016 06 01; 72(2):171-6.
Score: 0.027
-
Leukoplakia, Oral Cavity Cancer Risk, and Cancer Survival in the U.S. Elderly. Cancer Prev Res (Phila). 2015 Sep; 8(9):857-63.
Score: 0.025
-
Body mass index and early CD4 T-cell recovery among adults initiating antiretroviral therapy in North America, 1998-2010. HIV Med. 2015 Oct; 16(9):572-7.
Score: 0.025
-
Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009. Clin Infect Dis. 2013 Apr; 56(8):1174-82.
Score: 0.021
-
Short-term clinical outcomes among treatment-experienced HIV-positive patients with early low level viremia. AIDS Patient Care STDS. 2012 May; 26(5):253-5.
Score: 0.020
-
Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naïve patients. HIV Clin Trials. 2008 Nov-Dec; 9(6):367-74.
Score: 0.016
-
Influence of prior antiretroviral experience on adherence and responses to new highly active antiretroviral therapy regimens. AIDS Patient Care STDS. 2008 Apr; 22(4):301-12.
Score: 0.015
-
Effect of clinical pharmacists on utilization of and clinical response to antiretroviral therapy. J Acquir Immune Defic Syndr. 2007 Apr 15; 44(5):531-9.
Score: 0.014
-
Discontinuation of potent antiretroviral therapy: predictive value of and impact on CD4 cell counts and HIV RNA levels. AIDS. 2001 Nov 09; 15(16):2101-8.
Score: 0.010